News

Most Recent Press Releases

02/19/2012

Plexxikon Announces European Approval of Zelboraf® for the Treatment of Patients with BRAF Mutation-Positive Metastatic Melanoma

12/12/2011

Plexxikon Advances Novel Targeted Treatment of PLX3397 in Blood Cancer

11/13/2011

Plexxikon Novel Agents Aim To Address Cancer Treatment in New Ways

08/17/2011

Plexxikon Announces FDA Approval of Zelboraf™ (vemurafenib) and Companion Diagnostic for the Treatment of Patients with BRAF Mutation-Positive Metastatic Melanoma

06/05/2011

Plexxikon Reports Positive Data from Phase 3 and Phase 2 Trials of Vemurafenib (PLX4032)

Additional Press Releases

PR Contacts

Susan Kinkead
Kinkead Communications
415.751.3611
susan@kinkeadcomm.com

Jennifer Cook Williams
Cook Williams Communications
360.668.3701
jennifer@cwcomm.org